Jerome De Vente, MD

Principle Investigator
Long Beach Education and Research Consultants

Disclosure: Nothing to disclose

Presentation(s):

• 116 - Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study

  Oral Abstract